Concepedia

Publication | Open Access

Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis

20

Citations

8

References

2023

Year

Abstract

The results of this post hoc analysis suggest that tralokinumab is well tolerated and efficacious in patients 65 years or older with moderate-to-severe AD.

References

YearCitations

Page 1